TABLE 4.
Distribution of MICs of β-lactams against GBS clinical isolatesa
| Antimicrobial agent | No. (%) of strains with MIC (μg/ml) of:
|
||||||
|---|---|---|---|---|---|---|---|
| ≤0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | |
| Penicillin | 34 (7.7) | 280 (63.3) | 118 (26.7) | 7 (1.6) | 3 (0.7) | ||
| Ampicillin | 52b (11.8) | 313 (70.8) | 67 (15.1) | 10 (2.3) | |||
| Cefotaxime | 301b (68.1) | 114 (25.8) | 16 (3.6) | 11 (2.5) | |||
| Cefepime | 438b (99.1) | 3 (0.7) | 1 (0.2) | ||||
| Cefozopran | 35b (7.9) | 316 (71.5) | 72 (16.3) | 17 (3.8) | 2 (0.5) | ||
| Cefditoren | 399b (90.3) | 25 (5.7) | 11 (2.5) | 6 (1.3) | 1 (0.2) | ||
| Meropenemc | 365b (94.6) | 19 (4.9) | 2 (0.5) | ||||
a
A total of 442 isolates were tested.
b
Includes isolates with MICs less than the given value.
c
The number of isolates tested was 386.